ArticleBreathe (Sheffield, England)2023
Tuberculosis: current challenges and beyond.
Article in Breathe (Sheffield, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Diagnostic accuracy of stool Xpert MTB/RIF assay for adult pulmonary tuberculosis: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Anemia burden in tuberculosis patients across Southeast Asia: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Distribution of Mycobacterium Tuberculosis Lineages and Sublineages by Drug Profile in Ethiopia: A Systematic Review and Meta-Analysis.Journal of epidemiology and global health · 2025Pooled it
- Article
- Clinical Evaluation of a Tandem qPCR-CRISPR Assay for Multidrug-Resistant or Rifampicin-Resistant Tuberculosis: A Prospective Diagnostic Accuracy Study.Microorganisms · 2026Article
- Characterizing Tuberculosis Medication Side Effects Using Video Directly Observed Therapy Monitoring in Uganda: Opportunities for Digital Pharmacovigilance.Research square · 2026Article
- Predictive Ability of Sonographic Characteristics Alone to Diagnose Tuberculous Pleural Effusions in a Resource-Limited Setting: A Cross-Sectional Pilot Study in Zambia.Tropical medicine & international health : TM & IH · 2026Article
- A Comparative Policy Review of Tuberculosis Infection Control Policies Across Six Countries: Insights on Screening, Prevention, and Treatment Strategies.Health science reports · 2026Article
- Quality of life among tuberculosis patients in Lalitpur, Nepal: A cross-sectional study.Public health in practice (Oxford, England) · 2026Article
- Systematic modeling of porphyrin-based photosensitizers for inhibiting Mycobacterium tuberculosis β-Carbonic Anhydrases.Scientific reports · 2026Article
- The role of the UNITE4TB Young Investigators Group in empowering early career researchers through mentorship, capacity building, and innovation.IJTLD open · 2026Article
- Integrated Approach of Hematological Parameters and Glutathione as Predictors of Pulmonary TB Evolution: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Deciphering the Molecular Interactions of Tuberculosis and Colorectal Cancer: A Network and RNA-Seq Data Analysis Approach.Anti-cancer agents in medicinal chemistry · 2026Article
- A formative evaluation of the TB Think Tank's role and influence on TB policy in South Africa.PLOS global public health · 2026Article
- Lyophilized drug reservoir-integrated hydrogel-forming microarray patches for transdermal delivery of isoniazid and pyridoxine hydrochloride as a strategy to treat latent tuberculosis.Annals of translational medicine · 2025Article
- Cathepsin Z is a conserved susceptibility factor underlying tuberculosis severity.PLoS biology · 2025Article
- Structure-based design, synthesis, computational screening and biological evaluation of novel pyrrole fused pyrimidine derivatives targeting InhA enzyme.RSC advances · 2025Article
- Potential auxiliary diagnostic role of pentraxin 3 in plasma and bronchoalveolar lavage fluid for pulmonary tuberculosis.Journal of cardiothoracic surgery · 2025Article
- FuNTB: a functional network clustering tool for the analysis of genome-wide genetic variants in Mycobacterium tuberculosis.Bioinformatics (Oxford, England) · 2025Article
- Tuberculosis Care Quality Assessment: Evaluating Diagnosis and Treatment Effectiveness in Korea, 2018 to 2022.Tuberculosis and respiratory diseases · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite being a preventable and curable disease, tuberculosis (TB) is still a major global health threat and the second leading cause of death due to an infectious agent worldwide. All the efforts invested to end TB have resulted overall in rather slow decreases in TB incidence and mortality rates, which have been further negatively affected by the ongoing coronavirus disease 2019 (COVID-19) pandemic. While the majority of targets of the End TB Strategy remain off track, and we have not yet overcome the disruptions caused by the COVID-19 pandemic, recent conflicts such as the ongoing war in Ukraine are threatening the decrease of the burden of TB even further. To get back on track and get closer to ending TB, we need urgent, global, well-structured and committed multi-sectoral actions that go beyond national and global TB programmes with the support of deep investments in research and facilitation of equitable and rapid implementation of innovation worldwide.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.